Hidetoshi Itani

Department of Respiratory Medicine Ise Red Cross Hospital

关注

立即认领

关注

立即认领

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 35 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

Shinji Nakamichi,Kaoru Kubota,Toshihiro Misumi,Tetsuro Kondo,Shuji Murakami,Yoshimasa Shiraishi,Hisao Imai,Daijiro Harada,Kazutoshi Isobe,Hidetoshi Itani,Saori Takata,Hiroshi Wakui,Yuki Misumi,Satoshi Ikeda,Tetsuhiko Asao,Naoki Furuya,Shinobu Hosokawa,Yumiko Kobayashi,Yuichi Takiguchi,Hiroaki Okamoto

crossref（2024）

引用0浏览0引用

Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Impact of Immune‐related Adverse Events on Survival Outcomes in Extensive‐stage Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Tadashi Nishimura,Hajime Fujimoto,Takumi Fujiwara,Kentaro Ito,Atsushi Fujiwara,Hisamichi Yuda,Hidetoshi Itani,Masahiro Naito,Shuji Kodama,Kazuki Furuhashi, Akihiko Yagi,Haruko Saiki,Taro Yasuma,Tomohito Okano,Atsushi Tomaru,Motoaki Tanigawa,Masamichi Yoshida,Osamu Hataji,Hidenori Ibata,Corina N. D'Alessandro-Gabazza, Esteban C. Gabazza,Tetsu Kobayashi

CANCER MEDICINE（2024）

引用0浏览0WOS引用

Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

crossref（2024）

引用0浏览0引用

Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

CLINICAL CANCER RESEARCHno. 6 (2024): 1104-1110

引用0浏览0WOS引用

加载更多

作者统计

#Papers: 34

#Citation: 197

H-Index: 6

G-Index: 14

Sociability: 5

Diversity: 0

Activity: 1

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn